Ensign Group Posts Strong Q3 Revenue Growth, Net Income Up 6.9%
Ticker: ENSG · Form: 10-Q · Filed: Nov 3, 2025 · CIK: 1125376
Sentiment: bullish
Topics: Healthcare, Post-Acute Care, Skilled Nursing, Senior Living, REIT, Acquisitions, Financial Performance
Related Tickers: ENSG, SKH, NHC, LTC
TL;DR
**ENSG is aggressively expanding its healthcare footprint, driving solid revenue and profit growth, making it a compelling buy for long-term healthcare exposure.**
AI Summary
The Ensign Group, Inc. reported a robust financial performance for the three and nine months ended September 30, 2025. Total revenue for the three months increased by 19.8% to $1.296 billion from $1.082 billion in the prior year, driven primarily by a 19.9% rise in service revenue to $1.290 billion. Net income attributable to The Ensign Group, Inc. for the three months grew by 6.9% to $83.8 million, up from $78.4 million in the same period of 2024. For the nine months, total revenue climbed 18.2% to $3.697 billion from $3.128 billion, with net income attributable to the company increasing 13.8% to $248.5 million from $218.3 million. The company's total assets expanded to $5.226 billion as of September 30, 2025, from $4.669 billion at December 31, 2024, largely due to increases in property and equipment, net, and right-of-use assets. Cash and cash equivalents decreased by $20.9 million to $443.7 million for the nine months ended September 30, 2025, primarily due to significant cash payments for acquisitions totaling $240.3 million and purchases of property and equipment of $143.7 million.
Why It Matters
Ensign Group's continued revenue and net income growth signals strong operational execution in the post-acute care sector, which is crucial for investors seeking stability in healthcare. The significant increase in property and equipment, along with right-of-use assets, indicates aggressive expansion and investment in its facility network, potentially strengthening its competitive position against rivals like Genesis Healthcare or Kindred Healthcare. This expansion could lead to increased market share and long-term value for shareholders, while also providing more healthcare options for patients. However, the substantial cash outflow for acquisitions and capital expenditures highlights a strategy focused on growth, which, if mismanaged, could strain liquidity.
Risk Assessment
Risk Level: medium — The company's cash and cash equivalents decreased by $20.9 million for the nine months ended September 30, 2025, to $443.7 million, largely due to $240.3 million in cash payments for acquisitions and $143.7 million for property and equipment purchases. This aggressive investment strategy, while growth-oriented, could expose the company to integration risks and increased debt if not managed effectively, as evidenced by the $138.6 million in long-term debt.
Analyst Insight
Investors should consider ENSG for its consistent growth in revenue and net income, driven by strategic acquisitions and facility expansion. Monitor the company's debt levels and integration success of new facilities, but the current trajectory suggests continued market leadership in post-acute care.
Financial Highlights
- debt To Equity
- 0.15
- revenue
- $1.296B
- operating Margin
- N/A
- total Assets
- $5.226B
- total Debt
- $142.7M
- net Income
- $83.8M
- eps
- $1.46
- gross Margin
- N/A
- cash Position
- $443.7M
- revenue Growth
- +19.8%
Revenue Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Service revenue | $1.290B | +19.9% |
| Rental revenue | $6.6M | +16.6% |
Key Numbers
- $1.296B — Total Revenue (Q3 2025) (Increased 19.8% from $1.082B in Q3 2024)
- $83.8M — Net Income Attributable to ENSG (Q3 2025) (Increased 6.9% from $78.4M in Q3 2024)
- $3.697B — Total Revenue (YTD Q3 2025) (Increased 18.2% from $3.128B in YTD Q3 2024)
- $248.5M — Net Income Attributable to ENSG (YTD Q3 2025) (Increased 13.8% from $218.3M in YTD Q3 2024)
- $5.226B — Total Assets (Sept 30, 2025) (Increased from $4.669B at Dec 31, 2024)
- $240.3M — Cash Payments for Acquisitions (YTD Q3 2025) (Significant investment in growth)
- $143.7M — Purchase of Property and Equipment (YTD Q3 2025) (Indicates capital expenditure for expansion)
- 361 — Facilities Operated (As of September 30, 2025, across 17 states)
- 57,924,783 — Shares Outstanding (As of October 29, 2025)
- $1.46 — Basic EPS (Q3 2025) (Increased from $1.38 in Q3 2024)
Key Players & Entities
- ENSIGN GROUP, INC. (company) — Registrant and holding company for healthcare services
- Standard Bearer Healthcare REIT, Inc. (company) — Captive real estate investment trust (REIT) of Ensign Group
- NASDAQ Global Select Market (regulator) — Exchange where ENSG Common Stock is registered
- $1.296 billion (dollar_amount) — Total revenue for the three months ended September 30, 2025
- $83.8 million (dollar_amount) — Net income attributable to The Ensign Group, Inc. for the three months ended September 30, 2025
- $3.697 billion (dollar_amount) — Total revenue for the nine months ended September 30, 2025
- $248.5 million (dollar_amount) — Net income attributable to The Ensign Group, Inc. for the nine months ended September 30, 2025
- $240.3 million (dollar_amount) — Cash payments for acquisitions during the nine months ended September 30, 2025
- $143.7 million (dollar_amount) — Purchase of property and equipment during the nine months ended September 30, 2025
- September 30, 2025 (date) — End of the reported quarterly period
FAQ
What were The Ensign Group's key revenue drivers in Q3 2025?
The Ensign Group's total revenue for the three months ended September 30, 2025, was $1.296 billion, primarily driven by service revenue of $1.290 billion. This represents a 19.9% increase in service revenue compared to the same period in 2024.
How did Ensign Group's net income perform in the first nine months of 2025?
For the nine months ended September 30, 2025, net income attributable to The Ensign Group, Inc. increased to $248.5 million, up 13.8% from $218.3 million in the prior year period. This indicates sustained profitability growth.
What is Ensign Group's strategy regarding facility ownership and leasing?
As of September 30, 2025, Ensign Group's independent subsidiaries operated 361 facilities. Of these, 249 facilities are under long-term lease arrangements, with options to purchase eight. The company also owns 148 real estate properties, including 112 facilities operated by its subsidiaries and 36 leased to third-party operators.
What are the primary risks associated with Ensign Group's financial position?
A primary risk is the significant cash outflow for acquisitions, totaling $240.3 million for the nine months ended September 30, 2025. While indicative of growth, this aggressive investment could lead to integration challenges or increased financial leverage if not managed effectively.
How has Ensign Group's asset base changed in 2025?
Total assets for The Ensign Group increased to $5.226 billion as of September 30, 2025, from $4.669 billion at December 31, 2024. This growth was largely due to increases in property and equipment, net, which rose to $1.598 billion, and right-of-use assets, which reached $2.048 billion.
What is the role of Standard Bearer Healthcare REIT, Inc. within Ensign Group?
Standard Bearer Healthcare REIT, Inc. is Ensign Group's captive real estate investment trust. It owns and manages the company's real estate business and has elected to be taxed as a REIT for U.S. federal income tax purposes, providing an efficient vehicle for future property acquisitions.
What was Ensign Group's cash flow from operating activities for the nine months ended September 30, 2025?
For the nine months ended September 30, 2025, Ensign Group generated $380.95 million in net cash provided by operating activities. This is a substantial increase from $246.73 million in the same period of 2024, indicating strong operational cash generation.
How many shares of Ensign Group common stock were outstanding as of October 29, 2025?
As of October 29, 2025, there were 57,924,783 shares of The Ensign Group, Inc.'s common stock, $0.001 par value, outstanding.
What new accounting pronouncements might impact Ensign Group's future financial statements?
The company is evaluating ASU 2023-09, 'Improvements to Income Tax Disclosures,' effective for fiscal year 2025, and ASU 2024-03, 'Disaggregation of Income Statement Expenses,' effective for fiscal year 2027. Additionally, ASU 2025-06, 'Targeted Improvements to the Accounting for Internal-Use Software,' effective for fiscal year 2028, is under evaluation.
What was Ensign Group's basic earnings per share for the three months ended September 30, 2025?
The Ensign Group, Inc. reported basic earnings per share of $1.46 for the three months ended September 30, 2025. This is an increase from $1.38 in the corresponding period of 2024.
Risk Factors
- Healthcare Regulatory Environment [high — regulatory]: The healthcare industry is subject to extensive federal and state regulations, including Medicare and Medicaid participation requirements, licensure, and healthcare reform. Changes in these regulations could impact reimbursement rates and operational costs, potentially affecting profitability. For instance, shifts in healthcare policy could alter the demand for Ensign's services.
- Staffing and Labor Costs [high — operational]: The company relies on a significant number of skilled healthcare professionals. Shortages of qualified personnel or increased labor costs, driven by competitive market conditions or regulatory mandates, could adversely affect operating margins. For the nine months ended September 30, 2025, accrued wages and related liabilities increased to $370.5 million from $347.5 million in the prior year.
- Acquisition Integration and Financing [medium — financial]: Ensign's growth strategy involves acquisitions, which require significant capital outlay and successful integration. Failure to identify suitable acquisition targets, finance them effectively, or integrate them smoothly could hinder growth and impact financial performance. Cash payments for acquisitions totaled $240.3 million for the nine months ended September 30, 2025.
- Lease Obligations [medium — financial]: The company has substantial lease obligations, particularly for its facilities. Changes in lease accounting standards or increases in lease costs could impact financial statements and cash flows. Long-term lease liabilities (less current portion) stood at $1.903 billion as of September 30, 2025, up from $1.735 billion at December 31, 2024.
- Insurance and Self-Insurance Liabilities [medium — operational]: The company maintains self-insurance programs for certain risks, including professional liability and workers' compensation. Unforeseen claims or higher-than-expected claim costs could lead to significant financial liabilities. Accrued self-insurance liabilities (current and long-term) totaled $234.5 million as of September 30, 2025.
- Competition in Healthcare Services [medium — market]: The healthcare services market is highly competitive, with numerous providers offering similar services. Ensign faces competition from other skilled nursing facilities, assisted living facilities, and home health agencies. Maintaining market share and pricing power requires continuous investment in quality and efficiency.
- Interest Rate Sensitivity [low — financial]: While the company has a relatively low level of long-term debt ($138.6 million as of Sept 30, 2025), its significant lease liabilities are sensitive to interest rate fluctuations. Rising interest rates could increase the cost of financing new leases or refinancing existing ones, impacting profitability.
- Litigation and Legal Proceedings [medium — legal]: As a healthcare provider, Ensign is subject to potential litigation related to patient care, employment practices, and business operations. Adverse legal judgments or settlements could result in significant financial costs and reputational damage.
Industry Context
The healthcare services sector, particularly skilled nursing and senior living, is characterized by an aging population driving demand, but also by significant regulatory oversight and labor challenges. Ensign operates within a competitive landscape where quality of care, operational efficiency, and strategic acquisitions are key differentiators. Reimbursement rates from government programs like Medicare and Medicaid are critical revenue drivers, making regulatory changes a constant factor.
Regulatory Implications
Ensign's operations are heavily influenced by healthcare regulations, including those governing Medicare and Medicaid reimbursement, staffing levels, and patient care standards. Changes in these regulations, such as potential shifts in healthcare policy or increased compliance burdens, pose a significant risk. The company must maintain robust compliance programs to navigate this complex environment and avoid penalties.
What Investors Should Do
- Monitor acquisition pipeline and integration success.
- Analyze labor cost trends and staffing ratios.
- Assess the impact of lease liabilities on financial flexibility.
- Evaluate the company's self-insurance strategy.
- Track revenue growth drivers and margin sustainability.
Key Dates
- 2025-09-30: End of Q3 2025 — Reporting period for the 10-Q, showing strong revenue and net income growth.
- 2025-12-31: End of Fiscal Year 2024 — Balance sheet comparison point for total assets, which have grown significantly.
- 2024-09-30: End of Q3 2024 — Prior year comparison period for revenue and net income, highlighting year-over-year growth.
- 2025-10-29: Shares Outstanding Date — Indicates the number of shares outstanding as of a recent date, relevant for per-share calculations.
Glossary
- Right-of-use assets
- Assets that represent a lessee's right to use an underlying asset for the lease term. These are recognized under ASC 842 lease accounting standards. (Significant increase in these assets ($2.048B as of Sept 30, 2025) reflects the company's extensive facility leasing.)
- Non-controlling interest
- The portion of equity in a subsidiary that is not attributable to the parent company. It represents the ownership interest of outside shareholders. (A small but present component of total equity, indicating some consolidated subsidiaries are not wholly owned.)
- Accrued self-insurance liabilities
- Liabilities recognized for estimated future claims related to insurance policies that the company self-insures, such as professional liability or workers' compensation. (Represents a significant financial obligation ($160.6M long-term and $73.9M current as of Sept 30, 2025) due to the company's self-insurance strategy.)
- Goodwill
- An intangible asset that arises when a company acquires another company for a price greater than the fair value of its net identifiable assets. (A stable $98.0M indicates past acquisitions where the purchase price exceeded the fair value of net assets acquired.)
- Par value
- The nominal or face value of a stock or bond, as stated in the corporate charter or on the certificate itself. For Ensign's common stock, it is $0.001. (A nominal value that has minimal impact on the stock's market price or book value, but is a required accounting element.)
- Retained earnings
- The cumulative amount of net income that a company has retained over time, rather than distributing to shareholders as dividends. (A substantial and growing component of equity ($1.664B as of Sept 30, 2025), reflecting profitable operations.)
- Common stock in treasury
- Shares of the company's own stock that have been repurchased from the open market. These shares are not considered outstanding and do not have voting rights. (A negative balance (e.g., ($138.8M) as of Sept 30, 2025) reducing total equity, indicating share buybacks or shares held for employee stock plans.)
- Basic EPS
- Earnings per share calculated by dividing net income by the weighted-average number of outstanding common shares. (A key profitability metric for shareholders, showing $1.46 for Q3 2025, up from $1.38 in Q3 2024.)
Year-Over-Year Comparison
Compared to the prior year's comparable period, Ensign Group, Inc. has demonstrated robust top-line growth, with total revenue increasing by 19.8% to $1.296 billion in Q3 2025. Net income also saw an increase of 6.9% to $83.8 million, though the growth rate is lower than revenue, suggesting some margin pressure. Total assets have expanded significantly to $5.226 billion, driven by investments in property and equipment and acquisitions, while cash reserves have seen a slight decrease due to these strategic outlays. New risks related to integration of acquisitions and ongoing labor cost management are prominent.
Filing Stats: 4,697 words · 19 min read · ~16 pages · Grade level 15.1 · Accepted 2025-11-03 16:04:32
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share ENSG NASDAQ Global Select Mar
Filing Documents
- ensg-20250930.htm (10-Q) — 3210KB
- ensgq32025ex311.htm (EX-31.1) — 12KB
- ensgq32025ex312.htm (EX-31.2) — 12KB
- ensgq32025ex321.htm (EX-32.1) — 10KB
- ensgq32025ex322.htm (EX-32.2) — 10KB
- ensg-20250930_g1.jpg (GRAPHIC) — 13KB
- 0001125376-25-000170.txt ( ) — 12643KB
- ensg-20250930.xsd (EX-101.SCH) — 71KB
- ensg-20250930_cal.xml (EX-101.CAL) — 97KB
- ensg-20250930_def.xml (EX-101.DEF) — 383KB
- ensg-20250930_lab.xml (EX-101.LAB) — 846KB
- ensg-20250930_pre.xml (EX-101.PRE) — 643KB
- ensg-20250930_htm.xml (XML) — 2028KB
Financial Information
PART I. Financial Information Pg.
Financial Statements (unaudited)
Item 1. Financial Statements (unaudited): Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 1 Condensed Consolidated Statements of Income for the three and nine months ended September 30, 2025 and 2024 2 Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2025 and 2024 3 Condensed Consolidated Statements of Cash Flows for the n ine months ended Septe mber 30, 2025 and 2024 5 Notes to the Condensed Consolidated Financial Statements 7
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 31
Quantitative and Qualitative Disclosures About Market Risk
Item 3. Quantitative and Qualitative Disclosures About Market Risk 72
Controls and Procedures
Item 4. Controls and Procedures 73 P ART II. Other Information
Legal Proceedings
Item 1. Legal Proceedings 73
Risk Factors
Item 1A. Risk Factors 76
Other Information
Item 5. Other Information 108
Exhibits
Item 6. Exhibits 109
Signatures
Signatures Table of Contents PART I.
FINANCIAL STATEMENTS
Item 1. FINANCIAL STATEMENTS THE ENSIGN GROUP, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except par values) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 443,668 $ 464,598 Accounts receivable—less allowance for doubtful accounts of $ 7,948 and $ 8,435 at September 30, 2025 and December 31, 2024, respectively 612,744 569,897 Investments—current 62,641 62,255 Prepaid expenses and other current assets 87,525 60,882 Total current assets $ 1,206,578 $ 1,157,632 Property and equipment, net 1,598,401 1,291,354 Right-of-use assets 2,047,979 1,861,071 Insurance subsidiary deposits and investments 169,142 141,246 Deferred tax assets 56,125 66,281 Restricted and other assets 43,789 46,499 Intangible assets, net 6,442 7,292 Goodwill 97,981 97,981 TOTAL ASSETS $ 5,226,437 $ 4,669,356 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 105,796 $ 98,947 Accrued wages and related liabilities 370,530 347,532 Lease liabilities—current 110,817 93,475 Accrued self-insurance liabilities—current 73,854 67,331 Other accrued liabilities 160,042 132,057 Current maturities of long-term debt 4,191 4,086 Total current liabilities $ 825,230 $ 743,428 Long-term debt—less current maturities 138,557 141,585 Long-term lease liabilities—less current portion 1,902,946 1,735,325 Accrued self-insurance liabilities—less current portion 160,646 144,421 Other long-term liabilities 76,156 64,169 TOTAL LIABILITIES $ 3,103,535 $ 2,828,928 Commitments and contingencies (Notes 14 and 19) EQUITY Ensign Group, Inc. stockholders' equity: Common stock: $ 0.001 par value; 150,000 shares authorized; 61,461 and 57,897 shares issued and shares outstanding at September 30, 2025, respectively, and 60,838 and 57,438 shares issued and shares outstanding at December 31, 2024, respectively 61 61 Additional paid-in capital 593,781 528,052 Retained earnings 1,664,458 1,426,762 Common stock in